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Abstract
Background: Pheochromocytoma and reninoma represent two rare diseases causing hypertension. We here
reported a rare case of association between type 2 multiple endocrine neoplasia related bilateral pheochromocytoma
and reninoma. Moreover, polymorphism of ACE gene, which is known to be related to an increase of cardiovascular
risk, has been found in the same patient.
Case presentation: A 24 year old Caucasian man came to our attention for severe hypertension, resistant to
anti-hypertensive polytherapy. At the age of twenty he had undergone total thyroidectomy with lymphadenectomy
for medullary carcinoma. Genetic testing showed a RET mutation of codon 918 (exon 16) not documented in other
family members. During the follow-up, a progressive increase of urinary metanephrines and catecholamines was
recorded. Our evaluation confirmed the presence of severe hypertension (220/140 mmHg) and a severe increase
of urinary catecholamines and metanephrines. Due to the presence of hypokalemia, other causes of hypertension
were researched leading to the discovery of hyperreninemia (236 μUI/ml) with mild hyperaldosteronism, and a
mild increase of the renal artery resistance at ultrasound. An abdominal MRI showed multiple adrenal masses and
a right kidney nodular lesion of about 2 cm.
The patient underwent bilateral adrenalectomy and right nephrectomy, and histology confirmed the presence of
bilateral pheochromocytoma and right reninoma. The post-surgery laboratory evaluation showed a rapid reduction
of the urinary metanephrines while plasma renin level remained low in spite of the bilateral adrenalectomy
without any mineralocorticoid supplementation. To further investigate these unusual feature, we performed
genetic testing for the ACE gene, which revealed the presence of ACE I/D polymorphism.
Conclusion: This unique report describes the association between two rare causes of hypertension in the same
patient. Furthermore, the absence of requirement of mineralocorticoid supplementation in spite of bilateral
adrenalectomy, represent an uncommon and interest finding.
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Background
Pheochromocytoma (PHEO) and reninoma both repre-
sent two rare causes of juvenile hypertension. PHEO is a
neural crest-derived tumor, which produces and secretes
catecholamines and which is related to the classical clin-
ical symptoms associated with the inappropriate catechol-
amines secretion, such as are paroxysmal hypertension,
tachycardia, palpitations, headaches and sweating [1]. Even
if PHEO is a rare disease (less than 0.2% of patients with
hypertension [2]) the related cardiovascular symptoms
have a significant morbidity and even mortality. PHEO
can occur sporadically or as hereditary form related to
genetic background. In particular, type 2 multiple endo-
crine neoplasia (MEN2) is an autosomal dominant inher-
ited endocrine malignancy syndrome, due to germline
mutations in the REarranged during Transfection (RET)
proto-oncogene, which encodes a tyrosine kinase receptor
involved in cell growth, differentiation and survival. MEN
syndrome includes the following three subtypes: MEN2A
(association between medullary thyroid carcinoma [MTC],
PHEO and primary hyperparathyroidism); familial me-
dullary thyroid cancer and MEN2B. The latter repre-
sents a less common but more aggressive form and it is
characterized by the association between MTC and
PHEO with other particular features such as mucosal
neuromas, intestinal ganglioneuromas, and marfanoid
habitus with skeletal deformations and joint laxity [3].
Reninoma is a rare juxtaglomerular cell tumor causing
renin-mediated hypertension. This condition is usually di-
agnosed in adolescents and young adults and is typically
characterized by sustained hypertension well responding to
antihypertensive treatment targeting the renin-angiotensin-
aldosterone (RAA) system [4].
We here described a unique case of association between
bilateral MEN2B related PHEO in whom also a reninoma
causing secondary hyperaldosteronism was diagnosed.
Case presentation
Case report
In March 2010 a 24 year old Caucasian man with mar-
phanoid habitus (height: 175 cm; weight: 65 Kg) was re-
ferred to us for severe hypertension that was resistant to
beta blockers, angiotensin converting enzyme (ACE) in-
hibitors, and diuretics. Four years earlier he had under-
gone total thyroidectomy with lymphadenectomy due to
MTC (pT4N+; stage III UICC 2009). The preoperative
diagnostic workup had excluded PHEO, and his family
history was negative for MEN2B-related tumors. Genetic
testing for germline mutations in RET proto-oncogene
was not done. However, after his thyroid surgery a pro-
gressive increase of the urinary metanephrines and cate-
cholamines was noted, with absence of abnormal findings
at the magnetic resonance imaging (MRI) and metaiodo-
benzylguanidine (MIBG) scan.
At our clinical examination, a severe systo-diastolic
hypertension (220/140 mmHg) was observed, and muco-
sal neuromas of the tongue were found. Laboratory find-
ings included severe hypokaliemia (potassium 2.5 mEq/L),
hyperreninemia and mild hyperaldosteronism. Urinary
catecholamines were also increased, as well as urinary
metanephrines and vanil-mandelic acid. Inappropriate
cortisol secretion was ruled out on the basis of the pres-
ence of normal serum and urinary free cortisol and de-
tectable adrenocorticotropic hormone (ACTH) levels
(Table 1). An ultrasound of the kidneys revealed a mass
of approximately 2 cm at the right kidney with an
increased artery resistance (0.88; normal value < 0.7).
Furthermore, an enlargement of both adrenal glands
was detected.
The genetic test for RET germline mutations showed
the substitution of methionine for threonine in exon 16
at codon 918 (p.M918T) which was not present in other
family members (father, mother and sister). A recurrence
of MTC was excluded through assessment of serum
markers, showing undetectable levels of serum calci-
tonin and normal carcinoembryonic antigen (CEA)
levels, and an ultrasound of the neck which was nega-
tive. Replacement therapy with levothyroxine (150
mcg/day) appeared to be adequate and post-surgical
hypoparathyroidism was well controlled with calcitriol
(0.5 mcg/day).
An abdominal MRI confirmed the presence of adrenal
bilateral hyperplasia with multiple adrenal masses (16
and 18 mm in the right gland, and 10 and 15 mm in the
left gland), and the right kidney nodular lesion of 20 x
20 mm, hyperintensive in T2-weighted sequences. MIBG
scintigraphy showed bilateral adrenal uptake, strongly
suggestive for bilateral PHEO. Thus, the patient started
anti-hypertensive therapy with phenoxybenzamine 20 mg
four-times daily, nifedipine slow release 30 mg twice-daily,
and atenolol 50 mg once-daily. Blood pressure control
eventually improved. An ecocardiography showed dilated
cardiomyopathy and moderate systolic dysfunction (ejec-
tion fraction 46 %). One month later the patient under-
went bilateral adrenalectomy and right nephrectomy. No
hypertensive crisis occurred during the surgery. The tu-
mors were soft brown-red well-circumscribed masses
without cystic degeneration. Histology of the adrenal
glands confirmed the presence of bilateral and multi-
focal adrenal PHEO. No vascular or capsular invasion
was noted; mitotic figures were less than 3/10 high
power field and no atypical mitoses were present. The
Ki 67 index was 2 % and immunoistrochemistry was posi-
tive for chromogranin A and synaptophysin. The histology
of the right kidney mass revealed a capsulated neoplasm
with nests and diffused sheets of tumor cells interrupted
by abundant vascularity in the form of capillary channels
and sinusoids, which were suggestive for reninoma.
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After surgery, glucocorticoid replacement therapy with
hydrocortisone was immediately started together with
adequate hydration. Anti-hypertensive therapy was with-
drawn and blood pressure was low to normal. Labora-
tory evaluation showed a sudden reduction of urinary
metanephrines and catecholamines. Serum ACTH levels
increased accordingly to post-surgical hypoadrenalism
while serum cortisol was undetectable, but renin levels
were normal-low (10 μUI/ml), in the absence of min-
eralocorticoid supplementation. Currently, 3 years after
surgery, the patient is tumor-free. During this follow-up,
the patient has been treated with replacement therapy
comprised of hydrocortisone 30 mg, levothyroxine 150
mcg, and calcitriol 0.5 mcg.
Because of the persistence of normal renin values and
serum electrolytes (Table 1) and normal blood pressure
values mineralocorticoid substitutive therapy was not pro-
posed. Surprisingly, aldosterone serum levels were detect-
able in spite of bilateral adrenalectomy (Table 1). MRI
evaluation performed during follow-up failed to reveal ad-
renal remnants which could justify these clinical and bio-
chemical findings. Moreover, undetectable serum cortisol
performed about 18 h after the last hydrocortisone admin-
istration, was extremely suggestive for the absence of ad-
renal remnants or for the presence of ectopic functioning
adrenal tissue. To further investigate this unusual feature,
we hypothesized that it could be due to a dysregulation of
RAA axis. After obtaining the informed consent, we
searched for ACE polymorphisms. Genetic test revealed
ACE I/D polymorphism.
Gene analysis
After obtaining informed consent, genomic DNA was
isolated from peripheral blood by a manual method
(Roche Diagnostics, Basel, Switzerland, http://www.
roche.com/index.htm), while spectral analysis was per-
formed spectrophotometrically in order to determine
DNA concentration and purity (NanoPhotometer™, Implen,
München Germany, http://www.implen.de). Mutation ana-
lysis of the RET gene was performed by sequencing of cod-
ing region and exon-intron boundaries of the exons 2, 5, 8,
10, 11, 13–16. Primers used and the respective anneal-
ing temperatures are reported in Table 2. PCR products
were sequenced using the Big Dye Terminator v1.1
Cycle Sequencing kit (Applied Biosystems, Foster City,
CA, USA, http://www.appliedbiosystems.com/absite/us/
en/home.html) in an automated sequencer ABI Prism
3500 Genetic Analyzer (Applied Biosystems).
Finally, using the SeqScape® Software v2.5, sequences
were aligned to the reference sequence NG_007489.1.
For detecting ACE I/D polymorphism we followed the
molecular method reported in literature [5].
Discussion
We describe the unusual association between two very
rare conditions causing juvenile hypertension, bilateral
PHEO and reninoma, in a patient affected by MEN2B
and ACE-polymorphism. The coexistence of PHEO and
hyperreninemia secondary to renal artery stenosis has
been previously reported [6], while only a paper, which de-
scribed a 18 years follow-up in a family affected by MEN 2
B, found the association between adrenal medullary hyper-
plasia and renin-secreting juxtaglomerular tumor [7]. Fur-
thermore, we discovered in this patient the presence of
ACE gene I/D polymorphism which is known to be asso-
ciated with cardiovascular risk.
The estimated incidence of cathecolamine secreting tu-
mors is 2–8 per million, with the peak age of occurrence in
the third to fifth decade of life [8]. Recent population based
studies suggest that up to 32 % of patients have a germline
mutation in one of the known common susceptibility
genes [9]. In particular, mutations of VHL, NF1 and RET
cause well characterized cancer susceptibility syndrome
Table 1 Laboratory evaluation performed preoperatively, post-operatively and after 3 years of follow-up
Preoperative value Postoperative value Value after 3 years
of follow-up
Normal range
Reninemia (clinostatism) 236 μUI/ml 10 μUI/ml 25 μUI/ml 2.8–40 μUI/ml
Aldosterone (clinostatism) 536 pmol/L 267 pmol/L 186 pmol/L 55–415 pmol/L
Epinephrine 145 nmol/d 65 nmol/d 43 nmol/d 11–120 nmol/d
Norepinephrine 708 nmol/d 265 nmol/d 218 nmol/d 71–507 nmol/d
Metanephrine 15,681 nmol/d 310 nmol/d 225 nmol/d 253–1,720 nmol/d
Normetanephrine 6,932 nmol/d 479 nmol/d 615 nmol/d 491–2,430 nmol/d
Vanil-mandelic acid 15 mg/d 2 mg/d 3.6 mg/d <7 mg/d
ACTH 7 pmol/L 16 pmol/L 21 pmol/L 2.2–12.2 pmol/L
Serum cortisol 370 nmol/L <14 nmol/L <14 nmol/L 221–607 nmol/L
Urinary free cortisol 185 nmol/d Not performed Not performed 102–375 nmol/d
ACTH: adrenocorticotropic hormone; d: 24 h
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(von Hippel Lindau, Neurofibromatosis Type 1 and MEN2,
respectively).
These patients usually have other clinical characteris-
tics of the associated syndrome at time of presentation.
Moreover, mutations of mitochondrial succinate de-
hydrogenase (SDH) complex subunits genes (SDHA,
SDHB, SDHC, and SDHD) and one complex cofactor
(SDHAF2) have been reported in head and neck and
abdominal paragangliomas. Recently, other genes (TME
M127, MAX, HIF2A, EGLN1, KIF1B, H-RAS) have been
added to the group of susceptibility genes involved in the
development of paragangliomas/PHEO [10].
In our case, the association between MTC and PHEO,
which was diagnosed about 4 years after the diagnosis
of MTC, in addition to specific clinical features, was
strongly suggestive for MEN2B. Germline mutations in
RET codon 918 (M918T) were found to be related to the
classic MEN2B phenotype in 95 % of cases [11] but pa-
tients often lack a family history of MTC and harbor a
de novo mutation [12]. MEN 2B is the most severe form
of MEN 2: in normal conditions, activation of the RET
receptor involves interaction with different ligands which
triggers RET dimerization and determinates tyrosine kin-
ase activation. The M918T mutation can both induce a
conformational change in the kinase catalytic core leading
to the activation of RET without dimerization enhancing
the intrinsic kinase activity and alter the substrate specifi-
city of RET [13].
Genetic test performed in our patient showed the pres-
ence of M918T mutation (exon 16) confirming the diag-
nosis of MEN 2B, while screening performed in other
family members was negative. This mutation of RET pro-
toncogene was described as strongly associated with the
onset of PHEO [14].
In this patient both the presence of a syndrome predis-
posing to catecholamine-secreting tumors and the onset
of a severe juvenile hypertension, led to a work-up for
PHEO. Biochemical evaluation for the diagnosis of cathe-
colamine secreting tumors is based on the measurements
of fractionated metanephrines and cathecolamines in
urine or plasma, the latter not available in our Institution.
Urinary fractionated metanephrines and cathecolamines
show high sensitivity (97 and 86 % respectively) and good
specificity (69 and 88 % respectively) in the diagnosis of
cathecolamine secreting tumors, while vanil-mandelic acid
provides superior specificity (95 %) but lower sensitivity
(64 %) [15].
About tumor localization, either computed tomography
(CT) or MRI are recommended and can identify more
than 95 % of tumors. However, the higher specificity in
detecting PHEO is guaranteed by nuclear medicine tech-
niques, which provides functional imaging. 123I-MIBG is a
guanethidine analogue resembling norepinephrine. For
this reason, MIBG scintigraphy is very useful and ex-
tremely specific for the diagnostic localization of PHEO
[16]. In our patient a bilateral tumor, which can occur in
about one third of MEN2 related PHEO, was found.
However, the patient was also evaluated for all other
possible causes of secondary hypertension, thus discov-
ering renin-dependent hyperaldosteronism. Eventually a
reninoma, suspected on the basis of biochemical evalu-
ation and radiological findings, was confirmed by post-
operative histology. Furthermore, a very particular finding
in this case is the occurrence of ACE gene polymorphism
detected post-operatively, which may represent an add-
itional cause of cardiovascular risk.
ACE induces the catalytic conversion of angiotensin I to
angiotensin II which represents a crucial step in the regu-
lation of the RAA axis in turn involved in the regulation
of blood pressure and serum electrolytes. However, ACE
can cleave other many substrates, including bradykinin
and substance P [17], and is probably responsible of other
effects. ACE is widely distributed throughout the body, in-
cluding central nervous system, surface of vascular endo-
thelium and epithelium of the renal proximal tubule [17,
18]. This raises the question about a possible local effect
of ACE in these sites. In fact, the multiple activities of
ACE are demonstrated by the phenotype exhibited by
ACE knock-out mice, which have profound hypotension,
hypoplastic renal medulla, but also some other abnormal-
ities (such as infertility) which are not present in knock-
out mice for other components of RAA system [19].
Table 2 Primers used for RET amplification and sequencing
Oligo
Name
Sequence (5′→ 3′) Annealing
Temperature
(Ta) [°C]
RET-2 F GCT TCC CCT GTT TCC TTT TC
RET-2R AGT GTC AGC GGC TGT GAT AA
RET-5 F CGT GCA GCA TTC TAA GGT CTC
RET-5R CAT GTC TGT AGG GTG CTG CT
RET-8 F TGC TCC TGG CAC TGT CTT
RET-8R TGG GGA CCA ATC ACT GTA CTC
RET-10 F GGA CAC TGC CCT GGA AAT A
RET-10R ACT CGC CTC CCA GCA ATT T
RET-11 F ATA CGC AGC CTG TAC CCA CT
RET-11R AAA TGG GGG CAG AAC ACA 58
RET-13 F CCA TCC TGA CCT GGT ATG GT
RET-13R AAA CAG GGC AGG AGC AGT AG
RET-14 F GTC CAC CCC CTT ACT CAT TG
RET-14R GTG GTG AGC CAT AGC ATG G
RET-15 F CCC CCG GCC CAG GTC TC
RET-15R GCT CCA CTA ATC TTC GGT ATC TTT
RET-16 F TCT CCT TTA CCC CTC CTT CC
RET-16R CAG TGA GGG GGT CAT TGC
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ACE polymorphism, first described in 1990, seems to
be one of the major factors influencing ACE levels. In
their report, Rigat et al. [20] reported a 287 base pair Alu
repeat in 16th intron of ACE (17q23), which was termed I
(insert) allele. Conversely, the lack of the repeat is D (dele-
tion) allele. It has been demonstrated that subjects with
D/D genotype have the highest serum ACE levels (50 %
more relative to I/I), heterozygous individuals (genotype
I/D) have intermediate ACE levels (25 % more relative to
I/I) while homozygous I/I have the lowest ACE levels [21].
The D/D genotype was found more frequently in patients
with myocardial infarction than in control subjects [22],
but other studies showed no correlation with coronary
disease or stroke [23]. The I/D genotype, which has been
detected in our patient, is described in association with
several condition as diabetic peripheral neuropathy [24],
risk of recurrent miscarriage [25] as well as hypertension
and cardiovascular disease.
A very important point, in our opinion, is the associ-
ation between ACE polymorphism, MEN2B-related PHEO
and reninoma, which can all contribute, through different
pathways, to severe juvenile hypertension.
To our knowledge, there are not data available in the
Literature to affirm the possibility of a common genetic
background which could justify this association. In par-
ticular, the possibility that reninoma could represent an-
other possible disorder in MEN 2 B syndrome can only be
supposed in consideration of the reported cases. However,
these findings do not justify the screening of hyperaldos-
teronism in all patients affected by MEN 2 B, unless se-
vere concomitant hypokaliemia is present, as in our case.
Moreover, this patient represents a unique model of
ACE I/D polymorphism in post-surgical hypoadrenalism,
condition in which aldosterone secreting tissue is “virtu-
ally” absent. The absence of adrenal remnants or ectopic
functioning adrenal tissue is supported by undetectable
serum cortisol values after adequate pharmacological
wash-out. Furthermore, postoperative radiological im-
aging excluded the presence of adrenal remnants. As
well known, in patients who have undergone bilateral
adrenalectomy, an increase of ACTH and renin levels is
expected, and subjects need both glucocorticoid and
mineralocorticoid replacement. In our patient, in spite
of the predictable increase of ACTH values, renin levels
were unexpectedly normal, while serum aldosterone
remained detectable. The low-normal renin levels that
were seen immediately after the removal of the reni-
noma may have been due to the persistent suppression
of the normal renin secretion by the reninoma, overrid-
ing the stimulation due to the reduction of aldosterone.
Surprisingly, the renin levels remained low-normal long
after the removal of both adrenal glands and the reninoma
and the patient did not need mineralocorticoid replace-
ment therapy and did not experience hypotension or
hyperkaliemia, as expected in a condition of mineralo-
corticoid defect. We can try to explain this particular
phenomenon by considering a possible extra-adrenal al-
dosterone production. In fact, the existence of extra-
adrenal sites of aldosterone synthesis, such as heart or
brain, has been clearly demonstrated [26] and an endogen-
ous corticosteroid biosynthesis after bilateral adrenalec-
tomy has been described [27], even if the contribution of
these sources to the circulating hormone levels is not
completely known. In fact, while mRNA levels of aldoster-
one synthase (CYP11B2) are about 100 to 10,000 times
lower in the normal human heart than in the human ad-
renal gland [28], the aldosterone synthase expression has
been found to be elevated in patient with heart failure. It
is well known that both inappropriate cathecolamine [29]
and aldosterone [28] secretion per se cause cardiac remod-
eling, similarly to what has been found in our patient who
developed dilated cardiomyopathy and impaired systolic
function. While we cannot exclude that the heart failure
may have resulted in an increase in aldosterone synthase
expression, on the other hand it is difficult to determine
whether the presence of the ACE I/D polymorphism may
have played a contributing role in this setting, except that
it likely worsened the degree of hypertension and reduced
the response to ACE-inhibitors which had been used for
several years to treat the patient.
A possible hypothesis involving the role of ACE I/D
polymorphism in explaining this particular biochem-
ical finding, is an increase of ACE activity in extra-
adrenal aldosterone biosynthesis. In fact, tissue expressing
a “local angiotensin-aldosterone axis”, such as kidneys,
heart and blood vessels, can generate angiotensin II inde-
pendently from systemic renin-angiotensin-aldosterone
axis [30].
We cannot exclude that ACE I/D polymorphism can en-
hance the synthesis of angiotensin II in “local angiotensin-
aldosterone axis”.
Conclusion
In conclusion, we describe a unique association of 3 inde-
pendent causes of hypertension. The most interesting
points (other than the association between two rare causes
of hypertension such as reninoma and bilateral MEN2B-
related PHEO) are the persistence of detectable aldoster-
one levels in spite of bilateral adrenalectomy and the
detection of ACE I/D polymorphism. We cannot confirm
whether these two findings are related or randomly associ-
ated. Although the data seem to suggest the potential for
an additional source of ectopic adrenal aldosterone pro-
duction that could justify the presence of normal renin
values and detectable aldosterone levels, the exact role of
the concomitant ACE I/D polymorphism and its impact
on the clinical features of this case are not known.
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Consent
Written informed consent was obtained from the pa-
tient for publication of this Case report. A copy of the
written consent is available for review by the Editor of
this journal.
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